Browse the evidence

Resmetirom is the first drug approved for MASLD, demonstrating histological efficacy in addressing both steatohepatitis and fibrosis.

Practitioners can consider resmetirom as a treatment option for MASLD.

The review discusses the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders.

Understanding the role of metabolic drugs in managing inflammatory comorbidities can enhance treatment strategies.

Metabolic drugs may be repurposed as direct anti-inflammatory agents.

Exploring the repurposing of metabolic drugs could lead to new anti-inflammatory therapies.

Treatment-limiting gastrointestinal side effects occurred in 16.7% of patients.

Clinicians should monitor for gastrointestinal side effects in patients taking semaglutide.

The translational application of browning agents in humans faces challenges.

Practitioners should be aware of the limitations when considering browning agents for treatment.

No significant associations were found between GLP-1 receptor agonists or SGLT2 inhibitors and risk of sepsis, abscess, gangrene, or other infections.

Practitioners can be reassured about the lack of infection risk associated with these medications.

The relationship among cardiovascular disease, chronic kidney disease, and metabolic diseases is recognized as 'cardiovascular-kidney-metabolic (CKM) syndrome'.

Clinicians should consider the interconnectedness of these diseases in treatment.

Specialist clinicians have historically approached cardiovascular, kidney, and metabolic disorders as separate diseases.

Clinicians may need to reconsider their treatment strategies to integrate care for CKM syndrome.

Obesity is projected to affect over half of the global population by 2035.

Healthcare providers should prepare for increased obesity-related challenges.

Advances in omics technologies have enabled the identification of molecular subtypes and candidate biomarkers for obesity.

Utilizing omics technologies can enhance personalized approaches to obesity treatment.

No significant heterogeneity of treatment effects was found by age, race, ethnicity, baseline BMI, or baseline HbA1c.

GLP-1 receptor agonists may be effective regardless of age, race, ethnicity, BMI, or HbA1c levels.

People with MASH and clinically significant fibrosis are at risk of progressing to cirrhosis and hepatocellular carcinoma.

Monitoring and intervention are crucial for patients with MASH and fibrosis.

The net financial impact to Medicare was estimated to be savings of $715 million over 10 years.

Healthcare policymakers should recognize the potential cost savings associated with semaglutide for Medicare.

Availability of semaglutide in Medicare for all FDA-approved indications would yield net savings ranging from $1.04 billion to $412 million over 10 years.

Healthcare providers should advocate for the inclusion of semaglutide in Medicare to maximize economic and health benefits.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of the population.

Health practitioners should be aware of the high prevalence of MASLD in their patient populations.

The optimized nanocomplex of semaglutide with protamine and zinc exhibited a particle size of 196.0 nm and a zeta potential of -45.7 mV.

The nanocomplex's size and charge may influence its delivery and efficacy.

The nanocomplexes showed markedly delayed release of semaglutide, with only 19% drug release over 7 days.

The delayed release may improve the effectiveness of semaglutide in clinical settings.

Key chemobiological mechanisms implicated in obesity include dysregulated leptin-ghrelin signaling, chronic low-grade inflammation, and altered adipokine profiles.

Understanding these mechanisms can help in developing targeted interventions for obesity.

There is an urgent need for fundamental research to understand the mechanisms of metabolic disorders and cardiovascular disease.

Invest in research to better understand and treat metabolic and cardiovascular diseases.

Advances in understanding molecular causes of rare genetic obesities have led to therapies targeting appetite regulation.

Practitioners should consider new therapies targeting appetite regulation for patients with rare genetic obesities.

Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and bile acid receptors including the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5).

Practitioners should stay informed about these novel molecular targets for potential future therapies in obesity management.

Further research is needed to assess the long-term safety of Tirzepatide, particularly regarding cardiovascular outcomes.

Practitioners should be aware of the need for ongoing evaluation of Tirzepatide's long-term safety profile.

Interdisciplinary collaboration and communication between anaesthetists, surgeons, general practitioners, and endocrinologists are required to further investigate and establish preoperative guidelines for safe GLP-1 agonist use.

Healthcare teams should work together to create and follow guidelines for managing patients on GLP-1 agonists in surgical settings.

Collagen and free amino acid ingestion did not significantly increase myofibrillar protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance muscle protein synthesis in healthy individuals post-exercise.